If you take long-term statins, calcium channel blockers, or immunosuppressants, check the package insert for grapefruit interactions; avoid grapefruit, pomelos, Seville oranges, and their juices

Grapefruit contains compounds that permanently block an enzyme in your small intestine responsible for breaking down certain medications. As a result, far more of the active drug enters your bloodstream than intended—effectively turning a standard therapeutic dose into a multi-fold overdose without changing your pill count. A single whole grapefruit or an 8-ounce glass of juice is enough to trigger this effect, and its inhibition persists for 24 to 72 hours. This can cause severe muscle breakdown (rhabdomyolysis), acute kidney failure, dangerous blood pressure crashes, or potentially fatal cardiac arrhythmias (torsades de pointes). Pomelos and bitter Seville oranges share this mechanism; standard sweet table oranges do not.

Cost

Zero cost. Review the "Drug Interactions" and "Precautions" sections of the package insert for any regular prescription medication. If grapefruit is listed, eliminate grapefruit, pomelos, Seville oranges, limes, and their juices while on the medication. If you strongly prefer eating grapefruit, consult your prescribing physician or clinical pharmacist to switch to an unaffected alternative medication.

Benefit

A comprehensive clinical pharmacology review published in CMAJ (2013) identified over 85 medications that interact with grapefruit, with more than 43 capable of causing severe adverse events. Severe outcomes documented in clinical case reports include torsades de pointes (a lethal ventricular arrhythmia), rhabdomyolysis resulting in acute kidney injury, complete heart block, myelosuppression, respiratory depression, and gastrointestinal hemorrhage. Furanocoumarins (chiefly bergamottin and 6',7'-dihydroxybergamottin) in grapefruit irreversibly inactivate intestinal cytochrome P450 3A4 (CYP3A4), the primary first-pass metabolic enzyme for numerous oral medications. Because oral bioavailability surges, serum concentrations reach toxic levels. For the calcium-channel blocker felodipine, taking a dose with a single serving of grapefruit juice triples average systemic exposure compared to water (with individual variations ranging from 0x to over 8x). For statins, consuming 200 mL of grapefruit juice daily for 3 days increases systemic exposure (AUC) of simvastatin to 330% of normal, and atorvastatin to 180%–250%, substantially heightening myopathy and rhabdomyolysis risks. By contrast, pravastatin, rosuvastatin, and fluvastatin do not rely on CYP3A4 and remain unaffected. Peak inhibition occurs within 4 hours of ingestion, with 50% inhibition remaining at 10 hours and ~25% remaining at 24 hours. The review notes that Seville oranges (frequently used in marmalade), pomelos, and limes also contain furanocoumarins and produce the same inhibition. Common sweet oranges (such as navel or Valencia) lack furanocoumarins and do not interact with CYP3A4. The U.S. FDA explicitly warns patients taking simvastatin, atorvastatin, and nifedipine to avoid grapefruit juice, emphasizing that excessive accumulation in the body escalates liver and muscle damage, potentially leading to renal failure.

Notes

Not all drugs within a given therapeutic class interact with grapefruit; susceptibility depends strictly on CYP3A4 first-pass intestinal metabolism. Frequently prescribed interacting drugs include statins (simvastatin, lovastatin, atorvastatin), calcium-channel blockers (felodipine, nifedipine, amlodipine), antiarrhythmics (amiodarone, dronedarone), immunosuppressants (tacrolimus, cyclosporine), central nervous system agents (quetiapine, buspirone), and analgesics (oxycodone). Conversely, clopidogrel requires CYP-mediated bioactivation; grapefruit can reduce its active antiplatelet effect. When uncertain, always verify with your prescribing physician or dispensing pharmacist. The CMAJ review notes that adults over age 45 are both the highest consumers of grapefruit and the demographic most frequently prescribed interacting medications. Older adults taking felodipine with grapefruit juice face heightened risk of profound hypotension without compensatory tachycardia. Rated B because data originates from pharmacokinetic trials and clinical case cohorts rather than randomized mortality trials. Benefit rated Low because endpoints measure serum concentration surges rather than direct preventable population death counts.

Sources · 2

1. Bailey DG, Dresser G, Arnold JMO (2013). Grapefruit–medication interactions: forbidden fruit or avoidable consequences? CMAJ, 185(4):309-316. doi.org/10.1503/cmaj.120951
2. U.S. Food and Drug Administration (2021). Grapefruit Juice and Some Drugs Don't Mix. fda.gov/consumers/consumer-updates/grapefruit…